Skip to main content
Article thumbnail
Location of Repository

Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells

By Bérengère Marty, Virginie Maire, Eléonore Gravier, Guillem Rigaill, Anne Vincent-Salomon, Marion Kappler, Ingrid Lebigot, Fathia Djelti, Audrey Tourdès, Pierre Gestraud, Philippe Hupé, Emmanuel Barillot, Francisco Cruzalegui, Gordon C Tucker, Marc-Henri Stern, Jean-Paul Thiery, John A Hickman and Thierry Dubois
Topics: Research Article
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2656897
Provided by: PubMed Central

Suggested articles

Citations

  1. (2008). A: Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet
  2. (2004). Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res
  3. (2007). Aurias A: Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res
  4. (2004). Barillot E: Analysis of array CGH data: from signal ratio to gain and loss of DNA regions. Bioinformatics
  5. (2008). Barillot E: ITALICS: an algorithm for normalization and DNA copy number calling for Affymetrix SNP arrays. Bioinformatics
  6. (2006). Barillot E: VAMP: visualization and analysis of array-CGH, transcriptome and other molecular profiles. Bioinformatics
  7. (2003). Botstein D: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA
  8. (2008). BT: An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res
  9. (2007). Cancer research. Probing the roots of race and cancer. Science
  10. (2006). Cantley LC: Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature
  11. (2007). Coombes RC: Triple-negative breast cancer: therapeutic options. Lancet Oncol
  12. (2006). Cryns VL: Deconstructing the molecular portrait of basal-like breast cancer. Trends Mol Med
  13. (2007). DF: American Society of Clinical Oncology/ College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
  14. (2008). Essential roles of PI(3)Kp110beta in cell growth, metabolism and tumorigenesis. Nature
  15. (2003). ET: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA
  16. (2001). Eystein Lonning P, BorresenDale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA
  17. (2004). F: A Model-Based Background Adjustment for Oligonucleotide Expression Arrays.
  18. (2005). Foekens JA: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet
  19. (2006). Ganesan S: X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell
  20. (2005). GB: Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov
  21. (2006). Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell
  22. (2007). Helman LJ: Rapamycin induces feedback activation of Akt signaling through an IGF1R-dependent mechanism. Oncogene
  23. (2003). Huang AT: Gene expression predictors of breast cancer outcomes. Lancet
  24. (2007). Integrated profiling of basal and luminal breast cancers. Cancer Res
  25. (2008). IO: Basal-like breast cancer: a critical review.
  26. (2007). JE: A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature
  27. (2001). JS: Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod Pathol
  28. (2006). LC: The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet
  29. (2006). Maehara Y: Activation of PI3K/Akt signaling and hormone resistance in breast cancer. Breast Cancer
  30. (2007). Maehara Y: Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma. Breast Cancer Res Treat
  31. (2008). Martens JW: Subtypes of breast cancer show preferential site of relapse. Cancer Res
  32. (2007). MD: Exploring the specificity of the PI3K family inhibitor LY294002. Biochem J
  33. (2004). Meric-Bernstam F: Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res
  34. (2004). Meric-Bernstam F: Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res
  35. (2008). Meta-analysis of gene-expression profiles in breast cancer: toward a unified understanding of breast cancer sub-typing and prognosis signatures. Breast Cancer Res
  36. (2000). Molecular portraits of human breast tumours. Nature
  37. (2008). Monni O: Deciphering downstream gene targets of PI3K/mTOR/p70S6K pathway in breast cancer.
  38. (2006). Moreau-Gachelin F: Phosphatidylinositol 4-phosphatase type II is an erythropoietin-responsive gene. Oncogene
  39. (2006). N: mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res
  40. (2004). Perou CM: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res
  41. (2006). Perou CM: Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol
  42. (2006). Petricoin EF 3rd: Array-based proteomics: mapping of protein circuitries for diagnostics, prognostics, and therapy guidance in cancer.
  43. (2005). Pusztai L: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res
  44. (2005). R: PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res
  45. (2007). RC: Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol
  46. (2004). Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. Ann Oncol
  47. (2002). SH: Gene expression profiling predicts clinical outcome of breast cancer.
  48. (2008). SH: Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias.
  49. (2007). Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer. Mod Pathol
  50. (2008). Stokoe D: A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isotype-selective inhibition.
  51. (2008). Tavassoli FA: Clinical and pathologic aspects of basal-like breast cancers. Nat Clin Pract Oncol
  52. The Curie Institute microarray dataset repository [ h t t p : / /
  53. (2006). The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics
  54. The R Project for Statistical Computing [http://www.rproject.org]
  55. (2007). Tokuda Y: Increased phosphorylation of Akt in triple-negative breast cancers. Cancer Sci
  56. (2005). Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
  57. (2008). Tutt AN: Triple negative tumours: a critical review. Histopathology
  58. (2004). Utz PJ: Protein microarrays for multiplex analysis of signal transduction pathways. Nat Med
  59. (2007). Vijver MJ van de: Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res
  60. (2005). Vincent-Salomon A: KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome. Mod Pathol
  61. (2007). Watabe K: Roles of AKT signal in breast cancer. Front Biosci
  62. (2007). WJ: The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.